



Navigating the Cellular Maze: Innovative Strategies for Targeted Drug Delivery in Cervical Cancer

¹Navdeep Singh*, ¹Abhinoor Jassal, ¹Harinder Singh

¹*School of Pharmacy, Desh Bhagat University, Mandi Gobindgarh, Punjab, India.*

Keywords

Cervical cancer, Targeted drug delivery, Nanotechnology, Personalized medicine, Immunotherapy

Abstract

Cervical Cancer is a major health concern around the world including those regions which are limited in healthcare resources. The intricacies of this illness necessitate new and alternate methods to help treat its complexities. Researchers are therefore exploring means of targeted drug delivery that would deliver medications right to the cancer cells, minimizing side effects elsewhere in the human body. That targeted approach can increase treatment effectiveness. There are a lot of delivery systems available such as nanoparticles, liposomes, polymeric micelles and micellar systems, hydrogels or local drug delivery devices. They address matters, such as drug resistance and ensuring the targeted site of the body receives the dose. On top of that, emerging targeting strategies involving tumor -specific ligands, immunotherapy, virotherapy, and gene therapy look promising to develop more selective and efficacious treatments at a preclinical stage. Through the heavy focus on the complicated cellular pathways implicated in cervical cancer, these new approaches will make way for increased individualized and efficacious treatments. There is a need for further research to be carried out in the area of targeted drug delivery and the evolving targeting strategy, which is apparent through the literature. It remains a central goal with continued development of these strategies; we already know that this herald increased clinical benefit and quality of life for cervical cancer patients worldwide. The synergy of novel drug delivery techniques combined with targeted approaches hold promise in modifications towards an era when cervical cancer can be better managed or even eradicated.

*Corresponding Author:

Mr. Navdeep Singh (singhnavdeep659@gmail.com)

Article Info

Received: 01May 2025, Received in revised form: 13 September 2025, Accepted: 18 September 2025, Available online: 10 October 2025

ISSN: 3049-2955/The authors © 2025, under exclusive license to the Sprout Publication

DOI: <https://doi.org/10.63785/2025.1.3.285293>

1. Introduction

Cervical cancer is an important global public health problem particularly in low- and middle-income countries where rates of disease and death due to the disease are traumatizing. One of the biggest root causes of this problem is no cancer treatment centers and screening system in those parts. In fact, worldwide there were approximately 570,000 new cases of the disease in just 2018 (close to equalizing or just slightly less than 6.6% of population) which highlights how entrenched this disease really is. Alas, it is the number one killer of women from cancer globally and here in the U.S. That notwithstanding, barriers to economic status are preventing many women from getting appropriate screening early and impact women cancer incidence rates differences [1]. Studies have proven cervical cancer in developed countries reduced by >50% due to public health interventions (awareness, screening, vaccination, and diet). This underscores yet again how powerful early detection and prevention can be. But we must not forget other cervix cancer risk factors that will possibly play a role besides

HPV -- like illiteracy, under-privileged status, early many children and birth, tobacco use, malnutrition, bad hygiene [2]. These are especially important in developing countries, where >80% of cases live. Screening programs and the use of HPV vaccination have led to optimistic findings for low incidence and death rates from cervical cancer [3], [4]. More Awareness and Education about cervical cancer should be done widely to tackle the problem particularly in low-income nations, where there are no preventive resources and knowledge is low. To mitigate this problem, educational initiatives and engaging of people to seek preventive health services are paramount to reducing the global burden of cervical cancer [5]. Eventually, government initiatives and advances in HPV detection and vaccination strategies have led to an acceptable level of care for cervical cancer, with so less new cases per year that numbers plateau or decline in the more affluent environments. We definitely know from a large number of studies on how to make treatment delivery methods more effective and ramp down treatment side effects [6], [7].

Table 1 presents emerging drug delivery strategies

designed to improve the treatment of cervical cancer by enhancing drug concentration at the tumor site, reducing systemic side effects, and improving patient outcomes. Localized methods such as lipid-based nanocarriers and vaginal delivery allow targeted administration, while nanocarriers and nanotechnology-based systems improve solubility, bioavailability, and tumor specificity [8], [9]. Intravaginal nanomedicine further increases mucosal penetration and efficacy. In addition, immune

checkpoint inhibitors, targeted therapies, and specialized delivery systems help overcome resistance and reduce toxicity. Combined approaches, such as cisplatin with surgery or Bevacizumab with systemic therapies, have also shown improved survival, particularly in high-risk and recurrent cases. Overall, these strategies highlight the shift toward safer, more effective, and patient-centered treatments for cervical cancer [10], [11].

Table 1: Different drug delivery strategies for cervical cancer with advantage.

S. No.	Drug Delivery Strategy	Advantages	References
1.	Lipid-based nanocarriers, gels, nanoparticles, polymeric films, rods, and wafers (localized drug delivery methods)	Higher drug concentration at the intended location, better therapeutic results, and fewer side effects.	[12],[13]
2.	Delivery of drugs vaginally	Reduced systemic adverse effects, lower drug dosages, direct administration to the site of action, advantages for fertility-sparing surgery, and a decreased chance of recurrence.	[14],[15]
3.	Nanocarriers: hydrogels, dendrimers, liposomes, and nanoparticles	Safer alternatives to conventional chemotherapy, targeted and localized drug delivery against cervical cancer.	[16],[17]
4.	Nanotechnology facilitated nanocarriers	Enhanced drug solubility, bioavailability, targeted toxicity in cervical tumor cells.	[18],[19]
5.	Nanomedicine for intravaginal delivery	Increased efficacy of therapy and mucosal penetration.	[20]
6.	Immune checkpoint inhibitor therapies, anti-angiogenesis, and targeted medication therapy	Overcoming adverse effects and drug resistance while increasing the effectiveness of targeted therapy.	[21]
7.	Delivery methods based on nanomaterials (liposomes, dendrimers, polymers)	Administration tailored to a tumor, decreased toxicity, and enhanced biocompatibility.	[22],[23]
8.	Specialized medication delivery methods	Not specified.	[24]
9.	Using cytotoxic drugs like cisplatin in conjunction with surgery early	Increased chances of survival for high-risk cervical cancer.	[25]. [26]
10.	Utilizing vaginal medication delivery methods for the local treatment of cervical cancer	Not specified.	[27]
11.	Bevacizumab in combination with systemic anti-neoplastic therapies	Increase overall longevity in cases of recurring or metastatic cervical cancer.	[28], [29]

2. Types of Drug Delivery Approaches

2.1. Nanoparticles and Liposomes

The development of fewer side effects, increased therapeutic effect, and tailor-made drug delivery in new therapeutic strategies for cervical cancer treatment has placed liposomes and nanoparticles in the spotlight as leading approaches. Liposome- and nanoparticle-dependent selective targeting of cervical cancer cells via various mechanisms helps circumvent physiological barriers [30], [31]. These carriers can be targeted to cervical cancer cells in vivo or through different physical processes. One mechanism includes the enhanced permeation and retention (EPR) effect, which allows nanocarriers to accumulate in tumor tissues, along with modifications resulting from receptor-mediated

delivery enhancement. Approaches such as "first lipid adhesion and then mucosal transfixation" and "first adhesion-transfixation then mucosal penetration" demonstrate how nanomedicine can cross biological barriers to deliver therapeutic agents effectively [32], [33]. Recent advances in the preparation of liposomes and nanoparticles have shown encouraging therapeutic outcomes in targeted cervical cancer treatment. For example, chitosan-coated solid lipid nanoparticles, especially for cisplatin delivery, have revealed modified therapeutic effects. Similarly, chitosan-coated Poly(D,L-lactide-co-glycolide) nanoparticles conjugated with folic acid have been used for the selective delivery of carboplatin, showing enhanced antiproliferative activity [34]. Ursolic acid nanoparticles have also

been shown to induce apoptosis in vitro and in vivo, impeding cervical cancer growth. Nevertheless, challenges remain, including the need to optimize distribution efficiency, reduce systemic toxicity, prevent multidrug resistance, and ensure stability and biocompatibility. Current research is increasingly focused on developing smart nanovectors capable of simultaneously targeting, imaging, and delivering drugs to patients [35], [36].

2.2. Polymeric Micelles and Hydrogels

Compared to today's reality of cervical cancer treatment outcomes, it is clear that novel strategies for medication delivery are required to improve efficacy and ultimately outcomes in the fight against this disease. Among polymeric macromolecules and hydrogels, polymeric micelles and hydrogels have advanced most recently due to their applications in cancer therapy, controlled release, and biocompatibility [37]. These materials have shown potential in both in vitro and in vivo studies, offering new approaches to treatment. Researchers have increasingly focused on developing biocompatible and viable methods of drug delivery particularly polymeric micelles, copolymers, and hydrogels as they show promise in targeting tumor sites, reducing systemic toxicity, and providing sustained drug release [38], [39].

Immunotherapy hydrogels for regional drug delivery have emerged as an important strategy in cancer immunotherapy, addressing challenges associated with systemic administration. Other studies have explored mucoadhesive nanogels designed for cervical cancer treatment, and formulations such as paclitaxel combined with β -cyclodextrin and polyacrylic acid-based polymers have demonstrated strong cytotoxicity against cancer cells [40]. These systems enhance targeted delivery, overcome multidrug resistance, and increase residence time in specific local sites, such as the vagina. Recent advances in hydrogels and polymeric micelles have shown encouraging results in preclinical studies, with thermosensitive hydrogels demonstrating particular promise in preventing recurrence of cervical cancer after surgical intervention [41], [42].

Additionally, PEG-based hydrogels have attracted significant attention in cancer treatment due to their high drug encapsulation capability, ease of modification, and excellent biocompatibility. These features represent important progress in material science and highlight the potential of hydrogels as controlled and targeted drug delivery systems for cervical cancer therapy [43].

2.3 Local Drug Delivery Devices

Intracervical devices, intrauterine systems, and other local drug delivery devices (LDDs) have gained popularity for the management of cervical cancer. Chemotherapeutic drugs can be delivered directly to the affected region using these devices, which are highly valued for reducing systemic side effects and potentially enhancing treatment efficacy [44]. This targeted approach may lead to better patient outcomes, including a decreased risk of local

recurrence after surgery [45], [46]. The precision of drug delivery accurately controlling dose, site of action, and timing plays a key role in maximizing therapeutic efficacy while minimizing systemic side effects, particularly supporting fertility preservation in women of reproductive age. Recent advancements in cervical cancer care include innovative devices such as intravaginal rings containing Alisertib, which allow localized, sustained drug delivery without provoking inflammatory responses. Such developments represent significant improvements in targeted therapy [47], [48].

However, challenges remain that affect the effectiveness and wider application of LDDs. Barriers include issues with device tolerability and patient adherence, concerns about pain and complications during implantation, and shortages of such devices in developing countries [49]. Another limitation is that some devices may not adequately deliver drugs directly into tumors, complicating both clinical and technological applications. Furthermore, these methods require close monitoring and supervision to ensure safety and effectiveness, which adds to the complexity of their clinical use [50].

3. Current Challenges in Cervical Cancer Treatment

Traditional chemotherapy is widely used to treat many forms of cancer, but it has significant limitations in cervical cancer treatment. Its systemic nature means that while it targets cancer cells, it also affects normal cells, leading to numerous adverse effects on patient health [51]. This non-specific action highlights the need for therapies that specifically target cancer cells or affected areas. Another major challenge is drug resistance, which often limits therapeutic options for advanced cervical cancer [52].

Targeted therapy represents a promising new frontier, acting directly on malignant cells or oncogenic pathways. These therapies offer a safer and more efficient approach by focusing on molecular changes unique to cancer cells. Developing such targeted therapies requires an understanding of the molecular biology of the disease, including the identification of specific biomarkers that can be precisely targeted [53], [54]. Evidence suggests that the success of cervical cancer treatment critically depends on effective drug delivery systems (DDS). Intravaginal DDS, for example, can provide locally controlled drug release directly to the tumor site, ensuring maximum drug concentration, reducing drug resistance, and minimizing systemic side effects [55]. These systems can enhance the efficacy of both conventional chemotherapeutic agents and targeted therapies. Ongoing research continues to optimize these delivery technologies, focusing on improved targeting, controlled release kinetics, and overall treatment effectiveness [56], [57].

4. Targeting Strategies in Cervical Cancer

A major advancement in targeted therapy is the use of tumor-specific ligands for cervical cancer. The goal is to identify biomarkers and molecular targets unique to cervical cancer cells, enabling the delivery

of less toxic and more efficient therapies tailored to the molecular signature of each patient's tumor. Precision medicine in cervical cancer has progressed with biomarkers such as programmed death ligand 1 (PD-L1), which guides patient enrollment in checkpoint inhibitor therapy. Tumor-specific ligands are particularly valuable in targeting estrogen receptors associated with HPV-induced cervical cancer, highlighting the role of molecularly targeted drugs in enhancing therapeutic specificity and efficacy [58].

The development of targeted treatments has expanded treatment options, including immunotherapy, virotherapy, and gene therapy. These approaches utilize oncolytic viruses, immune checkpoint inhibition (CTLA-4/PD-1/PD-L1), and gene-based therapies to correct mutations and enhance tumor cell immune markers [59]. Additionally, epigenetic biomarkers, such as gene methylation patterns and protein expression (e.g., cyclooxygenase-2, hypoxia-inducible factor 1 α , and epidermal growth factor receptor), offer opportunities for individualized therapy. By tailoring treatment to the genetic and molecular characteristics of the tumor, these strategies improve prognosis, optimize therapeutic response, and advance personalized care for cervical cancer patients [60], [61].

Figure 1 illustrates several strategies for targeting cervical cancer cells using gene therapy and combination treatments designed to enhance apoptosis, inhibit tumor growth, and improve overall survival. One approach involves the use of P53 combined with Polyamidoamine (AP-PAMAM), which induces cell cycle arrest and activates the mitochondrial apoptosis pathway. By specifically targeting the G1/S phase transition, this method prevents cancer cell proliferation and reduces migration and invasion, thereby limiting tumor progression [62]. Another strategy employs Gendicine (rAd-p53) in combination with paclitaxel, which inhibits vascular endothelial growth factor (VEGF), reducing angiogenesis, while simultaneously promoting apoptosis in cervical cancer cells. This dual action not only suppresses tumor growth but also enhances the effectiveness of chemotherapy [63], [64]. Additionally, the combination of Gendicine (rAd-p53) with radiotherapy has been associated with increased overall survival rates in clinical trials, as radiotherapy synergizes with p53 gene therapy to enhance tumor cell killing and improve patient outcomes. Collectively, these strategies highlight the multifaceted potential of p53-based gene therapy, whether used alone or alongside chemotherapy or radiotherapy, to arrest the cell cycle, induce apoptosis, inhibit tumor growth, and ultimately improve clinical outcomes in cervical cancer patients [65], [66].




Figure 1: Therapeutic Strategies Targeting Cervical Cancer Using Gene Therapy and Combination Treatments; P53-based gene therapy strategies in cervical cancer. (a) AP-PAMAM-mediated p53 induces G1/S arrest, mitochondrial apoptosis, and reduces migration/invasion. (b) Gendicine (rAd-p53) with paclitaxel suppresses VEGF, tumor growth, and promotes apoptosis. (c) Gendicine with radiotherapy enhances tumor cell killing and improves survival. These approaches highlight the therapeutic potential of combining p53 gene therapy with chemo- or

radiotherapy.

4.1. Clinical Applications and Future Prospects

In high-risk cervical cancer, both chemotherapy and surgery show promise for improving survival, particularly with cisplatin-based regimens, which have demonstrated activity against advanced and recurrent disease in Phase II studies. Inhibition of proliferating cell nuclear antigen (PCNA) represents a novel therapeutic target. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mTOR pathway has also emerged as a potential strategy, given its central role in tumor proliferation and survival, making it an effective line of defense against cervical cancer [67].

5. Cell-Penetrating Peptides

Further studies have investigated the use of bevacizumab combined with chemotherapy to improve survival in patients with metastatic or recurrent cervical cancer, addressing the limited availability of systemic antineoplastic agents. Natural compounds such as budaptene, scopoletin, osthole, and praeruptorin have demonstrated antitumoral and antiproliferative effects against cervical cancer cells, potentially reducing side effects of conventional therapy and sensitizing tumors to radiation or chemotherapy [68]. Targeted drug delivery strategies, including nanocarriers and local systems such as gels, nanoparticles, and polymeric films, have been extensively explored to deliver high drug concentrations to tumor sites. Additionally, emerging therapeutic approaches include immunotherapy, virotherapy, and gene therapy, with clinical trials investigating CTLA-4 blockade, PD-1/PD-L1 checkpoint inhibition, and oncolytic viruses as potential treatment strategies [69], [70].

6. Clinical Applications and Case Studies in Cervical Cancer

Recent advancements in drug delivery systems for cervical cancer have focused on both systemic and localized approaches to improve therapeutic efficacy and reduce side effects. Whether it is liposomes, hydrogels, nanoparticles, or intravaginal rings, patches, and films, researchers are exploring new delivery techniques. These strategies aim to minimize systemic side effects by improving drug delivery to the diseased site [71].

Local drug delivery systems, such as gels, nanoparticles, polymeric films, and rods, are mainly nanocarrier-based systems. Solubilization enables high drug concentrations at the target site, which can improve therapeutic efficacy and reduce toxicity. Hydrogels, liposomes, and nanoparticles have shown promise as safer and more effective methods for systemic or targeted delivery of drugs in cancer treatment, such as cervical cancer [72], [73]. Additionally, artificial strategies like cervical patches, films, and rings are being emphasized for the localized administration of medication at the tumor site, minimizing systemic side effects and reducing the need for large doses. Local drug delivery, as opposed to systemic delivery, offers numerous

advantages in the management of cervical cancer. This breakthrough in targeted cancer therapy not only reduces side effects but also lowers the required dosage. Ultimately, targeted drug delivery increases therapeutic effectiveness by delivering larger concentrations of the drug with minimal systemic toxicity [74], [75].

7. Patient Perspectives in Cervical Cancer

Important factors that affect a patient's general well-being are revealed through their candid observations of their actual experiences and quality of life, both during and after cervical cancer treatment. Physical, mental, and social well-being were highlighted in a comprehensive study on the quality of life among survivors of cervical cancer, underscoring the complex balance that is impacted by the illness and its treatment [76]. Patients receiving definitive chemotherapy and radiation therapy expressed specific concerns that affected their quality of life, though the study did not go into detail about these experiences. It did, however, emphasize the need to gain a greater understanding of patients' viewpoints throughout such intense therapies [77].

An important study with a 10-year follow-up period shed light on the quality-of-life following surgery for individuals with early-stage cervical cancer. The long-term effects of cancer treatment on survivors were better understood thanks to this longitudinal method, which also revealed significant effects on their social relationships, psychological well-being, and everyday activities [78]. Other studies examine health-related quality of life in individuals with locally advanced cervical cancer who underwent major surgery and neoadjuvant therapy [50]. Again, the focus was on assessing the ways these treatment techniques affect patients' views of their health and their general level of contentment with life following treatment, highlighting the critical role of tailored care approaches [79], [80].

It has been demonstrated that postoperative therapies greatly enhance cervical cancer patients' quality of life. Enhancements were noted in aspects such as relationships with others, mental health, and living environments, suggesting that rehabilitation and supportive care can significantly improve recovery and quality of life after surgery [81]. One important factor that has emerged for patients undergoing surgery for cervical cancer is the quality of their sexual life, particularly for those who are of childbearing age. This underscores the importance of addressing family dynamics and sexual health as part of comprehensive cancer care for young women, as this will improve their mental health recovery and post-treatment well-being [82], [83].

A thorough investigation of the quality of life for early-stage cervical cancer patients receiving various adjuvant therapy regimens was provided by a comparative analysis from the STARS research. This analysis is crucial in ensuring a patient-centered

approach to cancer care by guiding treatment decisions that align with patients' preferences and life goals [84]. The substantial influence of modern treatment modalities on women's self-reported health-related quality of life was highlighted by a systematic review. This study integrated patient-reported results from multiple research projects to present a comprehensive picture of how contemporary treatments impact survivors, providing valuable insights for enhancing care approaches [85].

The combined findings of this research highlight the importance of incorporating patient perspectives into the design of care for cervical cancer. Understanding the subtleties inherent in patients' experiences, expectations, and perceived quality of life helps direct the development of more compassionate, effective, and comprehensive treatment and support programs tailored to their individual needs [86], [87].

Conclusion

The evolving field of targeted drug delivery in cervical cancer represents a transformative approach to enhancing therapeutic efficacy and minimizing side effects. Innovative strategies, including localized drug delivery systems, nanocarriers, and nanomedicine, are addressing critical challenges such as drug resistance, systemic exposure, and transdermal penetration. With a deep understanding of the

cellular landscape of cervical cancer, these advancements hold great promise to revolutionize treatment approaches, offering patients improved efficacy and fewer adverse effects. As research continues to progress, interdisciplinary collaborations and ongoing exploration of new drug delivery modalities will be crucial to translating the clinical potential of targeted drug delivery systems into more effective, personalized, and less toxic treatments. Ultimately, these innovations have the power to significantly improve the quality of life and survival rates for cervical cancer patients, shaping the future of cancer therapy.

Acknowledgement

The authors gratefully acknowledge the support and facilities provided by the School of Pharmacy, Deshbaghat University, Mandi Gobindgarh, Punjab, for the successful completion of this review.

Author Contribution

NS; Conceptualized the study, **AJ** and **HS**; Prepared the manuscript draft.

Conflict of Interest

No conflicts of interest are disclosed by the authors.

Source of Funding

There is no funding available to conduct this study.

Reference

1. Z. Petersen et al., "Barriers to uptake of cervical cancer screening services in low-and-middle-income countries: a systematic review," *BMC Womens. Health*, 2022, doi: 10.1186/s12905-022-02043-y.
2. F. Chidyaonga-Maseko, M. L. Chirwa, and A. S. Muula, "Underutilization of cervical cancer prevention services in low and middle income countries: A review of contributing factors," 2015. doi: 10.11604/pamj.2015.21.231.6350.
3. O. Tapera, G. Dreyer, A. M. Nyakabau, W. Kadzatsa, B. Stray-Pedersen, and S. J. H. Hendricks, "Model strategies to address barriers to cervical cancer treatment and palliative care among women in Zimbabwe: a public health approach," *BMC Womens. Health*, 2021, doi: 10.1186/s12905-021-01322-4.
4. Rinki Vishwas, "Peptide-Based Therapeutics in Fungal Infections: Challenges and Innovations," *Curr. Pharm. Res.*, no. 250001, pp. 98–115, 2025, doi: 10.63785/cpr.2025.1.1.98115.
5. A. W. LaVigne, S. A. Trieman, T. C. Randall, E. L. Trimble, and A. N. Viswanathan, "Cervical cancer in low and middle income countries: Addressing barriers to radiotherapy delivery," 2017. doi: 10.1016/j.gore.2017.08.004.
6. A. D. Shrestha, D. Neupane, P. Vedsted, and P. Kallestrup, "Cervical cancer prevalence, incidence and mortality in low and middle income countries: A systematic review," 2018. doi: 10.22034/APJCP.2018.19.2.319.
7. T. Ali, "Chromatography and Spectroscopic Characterization of Nano-Carrier Pharmaceuticals," *Pharm. Nanotechnol.*, 2024, doi: 10.2174/0122117385319695240911115239.
8. A. Srinath, F. Van Merode, S. V. Rao, and M. Pavlova, "Barriers to cervical cancer and breast cancer screening uptake in low- and middle-income countries: a systematic review," 2023. doi: 10.1093/heapol/czac104.
9. Manisha Dev and Pallavi Chandel, "Nanostructured Lipid Carriers in Pulmonary Drug Delivery: Progress and Prospects," *Curr. Pharm. Res.*, pp. 131–143, 2025, doi: 10.63785/cpr.2025.1.1.131143.
10. A. K. Mezei et al., "Cost-effectiveness of cervical cancer screening methods in low- and middle-income countries: A systematic review," 2017. doi: 10.1002/ijc.30695.
11. K. Singh et al., "Recent Advances in the Synthesis of Antioxidant Derivatives: Pharmacological Insights for Neurological Disorders," *Curr. Top. Med. Chem.*, vol. 24, no. 22, pp. 1940–1959, 2024, doi: 10.2174/0115680266305736240725052825.
12. M. Mehta, T. A. Bui, X. Yang, Y. Aksoy, E. M. Goldys, and W. Deng, "Lipid-Based Nanoparticles for Drug/Gene Delivery: An Overview of the Production Techniques and Difficulties Encountered in Their Industrial Development," 2023. doi: 10.1021/acsmaterialsau.3c00032.
13. U. Majid, S. Kandasamy, K. Farrah, and M. Vanstone, "Women's preferences and experiences of cervical cancer screening in rural and remote areas: A systematic review and qualitative meta-

- synthesis,” 2019. doi: 10.22605/RRH5190.
14. C. McConville, “The therapeutic potential of vaginal drug delivery in the treatment of cervical cancer,” 2015. doi: 10.4155/tde.15.13.
 15. B. Vega Crespo et al., “Barriers and facilitators to cervical cancer screening among under-screened women in Cuenca, Ecuador: the perspectives of women and health professionals,” *BMC Public Health*, 2022, doi: 10.1186/s12889-022-14601-y.
 16. S. Gupta and M. K. Gupta, “Possible role of nanocarriers in drug delivery against cervical cancer,” *Nano Rev. Exp.*, 2017, doi: 10.1080/20022727.2017.1335567.
 17. M. Li, D. Wang, J. Huang, S. Luan, and Q. Wang, “Sexual Behaviors and Intimate Relationships of Sexual Partners of Young Patients with Early-Stage Cervical Cancer: A Qualitative Study,” *Int. J. Gen. Med.*, 2023, doi: 10.2147/ijgm.s437150.
 18. K. P. Medina-Alarcón et al., “Highlights in nanocarriers for the treatment against cervical cancer,” 2017. doi: 10.1016/j.msec.2017.07.021.
 19. A. Gadducci and S. Cosio, “Pharmacological treatment of patients with metastatic, recurrent or persistent cervical cancer not amenable by surgery or radiotherapy: State of art and perspectives of clinical research,” 2020. doi: 10.3390/cancers12092678.
 20. Y. Liu, Z. Yang, L. Feng, Y. Xia, G. Wei, and W. Lu, “Advance in Nanomedicine for Improving Mucosal Penetration and Effective Therapy of Cervical Cancer,” 2024. doi: 10.1002/sml.202303772.
 21. P. Ciciola, P. Cascetta, C. Bianco, L. Formisano, and R. Bianco, “Combining immune checkpoint inhibitors with anti-angiogenic agents,” 2020. doi: 10.3390/jcm9030675.
 22. M. Kreidieh, D. Mukherji, S. Temraz, and A. Shamseddine, “Expanding the Scope of Immunotherapy in Colorectal Cancer: Current Clinical Approaches and Future Directions,” 2020. doi: 10.1155/2020/9037217.
 23. L. W. Kivuti-Bitok, G. P. Pokhariyal, R. Abdul, and G. McDonnell, “An exploration of opportunities and challenges facing cervical cancer managers in Kenya,” *BMC Res. Notes*, 2013, doi: 10.1186/1756-0500-6-136.
 24. P. Merle, “The new immuno-oncology-based therapies and their perspectives in hepatocellular carcinoma,” 2021. doi: 10.3390/cancers13020238.
 25. J. Yu et al., “An Open Label, Multicenter Clinical Study of Cetuximab Combined with Concurrent Chemo-radiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: Preliminary Results of a Phase II Trial,” *Int. J. Radiat. Oncol.*, 2010, doi: 10.1016/j.ijrobp.2010.07.733.
 26. Shamim, S. Ali, T. Ali, H. Sharma, B. N. Kishor, and S. K. Jha, “Recent Advances in Monodisperse Gold Nanoparticle Delivery, Synthesis, and Emerging Applications in Cancer Therapy,” *Plasmonics*, vol. 20, no. 1, 2025, doi: 10.1007/s11468-024-02732-4.
 27. I. Major and C. McConville, “Vaginal drug delivery for the localised treatment of cervical cancer,” 2017. doi: 10.1007/s13346-017-0395-2.
 28. C. M. Fisher and T. E. Schefter, “Profile of bevacizumab and its potential in the treatment of cervical cancer,” 2015. doi: 10.2147/OTT.S73251.
 29. M. R. Khan, D. Kumar, S. Shamim, K. Sunand, S. Sharma, and G. Rawat, “Ethnopharmacological relevance of Citrus limon (L.) Burm. f. as adjuvant therapy,” *Ann. Phytomedicine An Int. J.*, vol. 12, no. 2, pp. 169–179, 2023, doi: 10.54085/ap.2023.12.2.19.
 30. F. Ordikhani et al., “Drug delivery approaches for the treatment of cervical cancer,” 2016. doi: 10.3390/pharmaceutics8030023.
 31. Sawood Alam et al., “Overview of the Vital Role of Vitamin D: Functions, Deficiency Syndromes, and Impact Throughout Life,” *Curr. Pharm. Res.*, pp. 1–12, 2025, doi: 10.63785/cpr.2025.1.1.125136.
 32. B. Yu, H. C. Tai, W. Xue, L. J. Lee, and R. J. Lee, “Receptor-targeted nanocarriers for therapeutic delivery to cancer,” 2010. doi: 10.3109/09687688.2010.521200.
 33. A. K. Jaiswal et al., “Multi-targeted therapeutic exploration of Tamarix gallica flowers for anti-ulcer activity and associated complications,” *J. Ayurveda Integr. Med.*, vol. 15, no. 4, p. 100947, 2024, doi: 10.1016/j.jaim.2024.100947.
 34. J. Sharifi-Rad et al., “Chitosan nanoparticles as a promising tool in nanomedicine with particular emphasis on oncological treatment,” 2021. doi: 10.1186/s12935-021-02025-4.
 35. L. Wang, Q. Yin, C. Liu, Y. Tang, C. Sun, and J. Zhuang, “Nanoformulations of Ursolic Acid: A Modern Natural Anticancer Molecule,” 2021. doi: 10.3389/fphar.2021.706121.
 36. K. Singh et al., “Deciphering the Genetic Landscape: Exploring the Relationship Between HLA-DQA1, HLA-DQB1, and HLA-DRB1 Genes in Diabetes Mellitus,” *Curr. Pharmacogenomics Person. Med.*, vol. 21, pp. 1–11, 2024, doi: 10.2174/0118756921310081240821065036.
 37. H. Cho, T. C. Lai, K. Tomoda, and G. S. Kwon, “Polymeric Micelles for Multi-Drug Delivery in Cancer,” *AAPS PharmSciTech*, 2014, doi: 10.1208/s12249-014-0251-3.
 38. C. Sun et al., “Redox-sensitive polymeric micelles with aggregation-induced emission for bioimaging and delivery of anticancer drugs,” *J. Nanobiotechnology*, 2021, doi: 10.1186/s12951-020-00761-9.
 39. Navdeep Singh and Talit Masood, “Berberine in Breast Cancer Management: Molecular Mechanisms, Therapeutic Applications, and Future Directions,” *Curr. Pharm. Res.*, pp. 29–41, 2025, doi: 10.63785/cpr.2025.1.1.150160.
 40. E. S. Ali et al., “Targeting cancer cells with nanotherapeutics and nanodiagnostics: Current status and future perspectives,” 2021. doi: 10.1016/j.semcan.2020.01.011.
 41. R. Thipparaboina, R. B. Chavan, D. Kumar, S. Modugula, and N. R. Shastri, “Micellar carriers for the delivery of multiple therapeutic agents,” 2015. doi: 10.1016/j.colsurfb.2015.07.046.
 42. P. Kumar et al., “Fused Deposition Modeling 3D-Printed Scaffolds for Bone Tissue.pdf,” *Appl. Biochem. Biotechnol.*, vol. 12, no. 22, pp. 1–11,

- 2024, doi: 10.54085/ap.2023.12.2.19.
43. Q. R. Qi, H. Tian, B. Sen Yue, B. T. Zhai, and F. Zhao, "Research Progress of SN38 Drug Delivery System in Cancer Treatment," 2024. doi: 10.2147/IJN.S435407.
 44. A. Hailu and D. H. Mariam, "Patient side cost and its predictors for cervical cancer in Ethiopia: A cross sectional hospital based study," *BMC Cancer*, 2013, doi: 10.1186/1471-2407-13-69.
 45. L. M. Himiniuc et al., "Update on the Use of Nanocarriers and Drug Delivery Systems and Future Directions in Cervical Cancer," 2022. doi: 10.1155/2022/1636908.
 46. B. Pratap, S. Shamim, and S. Ali, "Formulation and Characterisation of Herbal Ethosomal Gel of Luliconazole and Clove Oil for Modified Drug Diffusion to the Skin," *Res. J. Pharm. Technol.*, vol. 18, no. 8, pp. 3501–3508, 2025, doi: 10.52711/0974-360X.2025.00504.
 47. A. Sugumaran and V. Mathialagan, "Colloidal Nanocarriers as Versatile Targeted Delivery Systems for Cervical Cancer," *Curr. Pharm. Des.*, 2020, doi: 10.2174/1381612826666200625110950.
 48. Shukar Singh, Gursewak Singh, Tawqeer Shafi, and Shafkat Hussain Malik, "Overview of Peptic Ulcer Disease: Epidemiology, Causes, Pathophysiology, and Clinical Importance," *Curr. Pharm. Res.*, pp. 68–79, 2025, doi: 10.63785/cpr.2025.1.2.184192.
 49. I. M. Puspitasari, D. Legianawati, R. K. Sinuraya, and A. A. Suwantika, "Cost-effectiveness analysis of chemoradiation and radiotherapy treatment for stage iib and iiib cervical cancer patients," *Int. J. Womens. Health*, 2021, doi: 10.2147/IJWH.S289781.
 50. P. Boyd, I. Major, W. Wang, and C. McConville, "Development of disulfiram-loaded vaginal rings for the localised treatment of cervical cancer," *Eur. J. Pharm. Biopharm.*, 2014, doi: 10.1016/j.ejpb.2014.08.002.
 51. J. Caren*, K. Kurgat, and G. Mose, "Health Care Providers' Communication: The Cancer Patients' Perspective-A Study among Cervical Cancer Patients in Uasin Gishu County, Kenya," *Int. J. Recent Innov. Med. Clin. Res.*, 2024, doi: 10.18231/j.ijrimcr.2020.004.
 52. C. A. Burmeister et al., "Cervical cancer therapies: Current challenges and future perspectives," 2022. doi: 10.1016/j.tvr.2022.200238.
 53. S. Ranga et al., "Long non-coding RNAs as critical regulators and novel targets in cervical cancer: current status and future perspectives," 2023. doi: 10.1007/s10495-023-01840-6.
 54. Murari Kumar Maharaj, Aman Kumar, Tawqeer Shaf, and Shafkat Hussain Malik, "Mouth-Dissolving Films: A Novel Approach for Oral Drug Delivery in Diabetic Management," *Curr. Pharm. Res.*, pp. 80–87, 2025, doi: 10.63785/cpr.2025.1.2.193199.
 55. Y. Tang, A. X. J. Zhang, G. Chen, Y. Wu, and W. Gu, "Prognostic and therapeutic TILs of cervical cancer—Current advances and future perspectives," 2021. doi: 10.1016/j.omto.2021.07.006.
 56. N. Abd Rashid, N. H. Mohamad Najib, N. A. Abdul Jalil, and S. L. Teoh, "Essential Oils in Cervical Cancer: Narrative Review on Current Insights and Future Prospects," 2023. doi: 10.3390/antiox12122109.
 57. A. Anand et al., "Neuroprotective Efficacy and Complementary Treatment with Medicinal Herbs: A Comprehensive Review of Recent Therapeutic Approaches in Epilepsy Management," *CNS Neurol. Disord. - Drug Targets*, vol. 24, no. 1, pp. 60–73, 2024, doi: 10.2174/0118715273332140240724093837.
 58. J. K. Jallah, A. Anjankar, and F. A. Nankong, "Public Health Approach in the Elimination and Control of Cervical Cancer: A Review," *Cureus*, 2023, doi: 10.7759/cureus.44543.
 59. S. Aballéa et al., "Risk factors for cervical cancer in women in China: A meta-model," *Women's Heal.*, 2020, doi: 10.1177/1745506520940875.
 60. D. Chu, T. Liu, and Y. Yao, "Implications of viral infections and oncogenesis in uterine cervical carcinoma etiology and pathogenesis," 2023. doi: 10.3389/fmicb.2023.1194431.
 61. Riya Chandel, Firoz Khan, and Taranvirinderdeep Singh, "The Expanding Role of Sphingolipids in Liver Fibrosis and Disease Progression," *Curr. Pharm. Res.*, pp. 88–104, 2025, doi: 10.63785/cpr.2025.1.2.200214.
 62. Á. Áyen, Y. J. Martínez, and H. Boulaiz, "Targeted gene delivery therapies for cervical cancer," *Cancers (Basel)*, 2020, doi: 10.3390/cancers12051301.
 63. S. Zhen et al., "Human Papillomavirus Oncogene Manipulation Using Clustered Regularly Interspersed Short Palindromic Repeats/Cas9 Delivered by pH-Sensitive Cationic Liposomes," *Hum. Gene Ther.*, 2020, doi: 10.1089/hum.2019.312.
 64. S. et al. Singh, K., Gupta, J. K., Chanchal, D. K., Khan, S., Varma, A., Shanno, K., Kumar, S., & Shamim, "Deciphering the Genetic Landscape: Exploring the Relationship Between HLA-DQA1, HLA-DQB1, and HLA-DRB1 Genes in Diabetes Mellitus," *Curr. Pharmacogenomics Person. Med.*, vol. 21, no. 3, pp. 1–11, 2024, doi: 10.2174/0118756921310081240821065036.
 65. H. Ye et al., "A novel targeted therapy system for cervical cancer: Co-delivery system of antisense Lncrna of mdcl and oxaliplatin magnetic thermosensitive cationic liposome drug carrier," *Int. J. Nanomedicine*, 2021, doi: 10.2147/IJN.S258316.
 66. Imanshu, Mohita Thakur, and Deepika Bhatia, "Ginkgo biloba Herbal Plant Used for Treating Dementia and Alzheimer's Disease," *Curr. Pharm. Res.*, pp. 105–115, 2025, doi: 10.63785/cpr.2025.1.2.215224.
 67. C. Gennigens et al., "Recurrent or primary metastatic cervical cancer: current and future treatments," 2022. doi: 10.1016/j.esmoop.2022.100579.
 68. K. S. Tewari et al., "Improved Survival with Bevacizumab in Advanced Cervical Cancer," *N. Engl. J. Med.*, 2014, doi: 10.1056/nejmoa1309748.

69. "Improved Survival with Bevacizumab in Advanced Cervical Cancer," *N. Engl. J. Med.*, 2017, doi: 10.1056/nejmx170002.
70. Mohita Thakur, "Importance of In-Process Quality Control for Product Safety and Integrity in Pharmaceutical Packaging," *Curr. Pharm. Res.*, pp. 116–124, 2025, doi: 10.63785/cpr.2025.1.2.225232.
71. U. Hani, R. Ali M. Osmani, R. R. Bhosale, H. Gurumallappa Shivakumar, and P. K. Kulkarni, "Current Perspectives on Novel Drug Delivery Systems and Approaches for Management of Cervical Cancer: A Comprehensive Review," *Curr. Drug Targets*, 2016, doi: 10.2174/1389450116666150505154720.
72. F. Islam et al., "Corrigendum to 'Multifaceted role of polyphenols in the treatment and management of neurodegenerative diseases' [Chemosphere 307 (2022) 136020] (Chemosphere (2022) 307(P3), (S0045653522025139), (10.1016/j.chemosphere.2022.136020)),", 2023, doi: 10.1016/j.chemosphere.2023.139655.
73. S. Chawla, R. Gupta, S. K. Jha, and K. T. Jha, "Stereoisomerism in Chemistry and Drug Development: Optical, Geometrical, and Conformational Isomers," *Med. Chem. (Los Angeles)*, 2025, doi: 10.2174/0115734064366389250923044201.
74. J. B. Wolinsky, Y. L. Colson, and M. W. Grinstaff, "Local drug delivery strategies for cancer treatment: Gels, nanoparticles, polymeric films, rods, and wafers," 2012, doi: 10.1016/j.jconrel.2011.11.031.
75. Tarmeen Ali, "Nanomedicine Approaches to Overcome Barriers in Pulmonary Drug Delivery for Respiratory Diseases," *Curr. Pharm. Res.*, pp. 30–44, 2025, doi: 10.63785/cpr.2025.1.1.3044.
76. C. D. Arvanitis, G. B. Ferraro, and R. K. Jain, "The blood–brain barrier and blood–tumour barrier in brain tumours and metastases," 2020, doi: 10.1038/s41568-019-0205-x.
77. C. M. O'Driscoll, A. Bernkop-Schnürch, J. D. Friedl, V. Pr  at, and V. Jannin, "Oral delivery of non-viral nucleic acid-based therapeutics - do we have the guts for this?," *Eur. J. Pharm. Sci.*, 2019, doi: 10.1016/j.ejps.2019.03.027.
78. K. A. Rendle et al., "Patient perspectives on delays in cervical cancer screening and follow-up care in Botswana: a mixed methods study," *BMC Womens. Health*, 2022, doi: 10.1186/s12905-022-01777-z.
79. N. K. R. L. Ekayanti, R. Noviyani, S. C. Yowani, K. Ariawati, and I. N. G. Budiana, "COST ANALYSIS OF PATIENTS WITH SQUAMOUS CELL CERVICAL CANCER STAGE IIB-IIIB WITH PACLITAXEL CISPLATIN CHEMOTHERAPY FROM THE SOCIETAL PERSPECTIVE," *J. Pharm. Sci. Appl.*, 2023, doi: 10.24843/jpsa.2023.v05.i01.p05.
- A. et al. Kumar, J., M., T., Musayev, "Stimuli-responsive Hydrogels for Targeted Antibiotic Delivery in Bone Tissue Engineering," *AAPS PharmSciTech*, vol. 26, no. 217, pp. 1–23, 2025, doi: <https://doi.org/10.1208/s12249-025-03218-0>.
80. L. B. Bateman et al., "Barriers and Facilitators to Cervical Cancer Screening, Diagnosis, Follow-Up Care and Treatment: Perspectives of Human Immunodeficiency Virus-Positive Women and Health Care Practitioners in Tanzania," *Oncologist*, 2019, doi: 10.1634/theoncologist.2017-0444.
81. T. Lozar, R. Nagvekar, C. R. Racheal, S. D. Mandishora, U. I. Megan, and B. Fitzpatrick, "Cervical cancer screening postpandemic: Self-sampling opportunities to accelerate the elimination of cervical cancer," 2021, doi: 10.2147/IJWH.S288376.
82. S. A. Ali, S. Ali, S. Rastogi, B. Shivhare, and M. Muztaba, "A Comprehensive Review on Advancements in Nanocarriers-Based Peptide Delivery for Cancer Therapeutics," *Micro Nanosyst.*, vol. 17, no. 4, pp. 283–297, 2025, doi: 10.2174/0118764029358553250325040749.
83. H. W. Kim et al., "Clinical nurses' awareness and caring experiences for patients with cervical cancer: A qualitative study," *PLoS One*, 2019, doi: 10.1371/journal.pone.0217201.
84. B. E. Lott et al., "Health workers' perspectives on barriers and facilitators to implementing a new national cervical cancer screening program in Ethiopia," *BMC Womens. Health*, 2021, doi: 10.1186/s12905-021-01331-3.
85. A. C. Des Marais, N. T. Brewer, S. Knight, and J. S. Smith, "Patient perspectives on cervical cancer screening interventions among underscreened women," *PLoS One*, 2022, doi: 10.1371/journal.pone.0277791.
86. P. Kumar et al., "Trends of Nanobiosensors in Modern Agriculture Systems," *Appl. Biochem. Biotechnol.*, vol. 197, no. 1, pp. 667–690, 2024, doi: 10.1007/s12010-024-05039-6.